Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results
10 nov. 2021 05h55 HE
|
Novan, Inc.
– Company executing on plans for three potential New Drug Application (NDA) filings in three years with the first submission targeted in Q3 2022 for lead program SB206 in molluscum contagiosum – –...
Novan Completes End-of-Phase 2 Meeting and Provides Additional Business Updates
11 mars 2019 08h00 HE
|
Novan, Inc.
Completed end-of-Phase 2 FDA meeting for molluscum contagiosumMeeting minutes received and support second quarter 2019 pivotal Phase 3 initiationFinalizing establishment of Irish entity to enable EU...
Novan Extends Technical Production Capacity and Reaches Agreement with Orion Corporation
16 oct. 2018 08h05 HE
|
Novan, Inc.
External manufacturing agreement reached to enable production of clinical trial materials for SB204 and the acne indication, with the potential to include additional product candidatesExtension of...
Novan Expands Nitric Oxide Dermatology Business Partnership with Sato in Japan
08 oct. 2018 08h00 HE
|
Novan, Inc.
Expanded license agreement adds SB206 for the treatment of viral skin infections Novan to receive upfront cash consideration of approximately 1.25 billion JPY (~$11.0 million), payable over the next...
Novan Receives FDA Guidance for SB204 and Acne Indication
24 sept. 2018 16h15 HE
|
Novan, Inc.
Written minutes received from Type C meeting with FDAModerate-to-severe patient pathway re-affirmedAdditional insights gained around the severe patient sub-population MORRISVILLE, N.C., Sept. 24,...
Novan to Present Integrated Data from Phase 3 Trials with SB204 for Treatment of Acne
13 févr. 2018 08h05 HE
|
Novan, Inc.
MORRISVILLE, N.C., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that data from the Company’s two Phase 3 clinical trials and long-term...
Novan Announces Plan to Complete Development of SB204 Acne Candidate via Third Party Funding and Execution
07 nov. 2017 08h05 HE
|
Novan, Inc.
MORRISVILLE, N.C., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that it has agreed in principle to a business structure that would enable...
Novan Conducts Guidance Meeting with FDA on SB204 Development Program
25 sept. 2017 08h00 HE
|
Novan, Inc.
MORRISVILLE, N.C., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that it has concluded a guidance meeting with the U.S. Food and Drug...
Novan to Present Safety and Efficacy Data for SB204 Program in Adolescents at 13th World Congress of Pediatric Dermatology
07 juil. 2017 09h05 HE
|
Novan, Inc.
MORRISVILLE, N.C., July 07, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that pharmacokinetic, safety and efficacy data for SB204, an investigational...
Novan Presents Safety Data for SB204 Program
27 avr. 2017 09h13 HE
|
Novan, Inc.
MORRISVILLE, N.C., April 27, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that pharmacokinetic data for SB204, a once-daily, topical monotherapy for...